CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving
about
In vivo experience with natural scaffolds for myocardial infarction: the times they are a-changin'Contemporary perspective on endogenous myocardial regeneration.Foetal bovine serum-derived exosomes affect yield and phenotype of human cardiac progenitor cell cultureCardiac Repair and Regeneration: The Value of Cell Therapies.Micro- and Macrostructured PLGA/Gelatin Scaffolds Promote Early Cardiogenic Commitment of Human Mesenchymal Stem Cells In Vitro.Clinical trials of bone marrow derived cells for ischemic heart failure. Time to move on? TIME, SWISS-AMI, CELLWAVE, POSEIDON and C-CURE.Can heart function lost to disease be regenerated by therapeutic targeting of cardiac scar tissue?Wnt/β-catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration.Normal versus Pathological Cardiac Fibroblast-Derived Extracellular Matrix Differentially Modulates Cardiosphere-Derived Cell Paracrine Properties and CommitmentGetting Old through the Blood: Circulating Molecules in Aging and Senescence of Cardiovascular Regenerative Cells.Physiological and hypoxic oxygen concentration differentially regulates human c-Kit+ cardiac stem cell proliferation and migration.Pim1 Kinase Overexpression Enhances ckit+ Cardiac Stem Cell Cardiac Repair Following Myocardial Infarction in Swine.Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed.Recent Progress in Stem Cell Modification for Cardiac Regeneration.Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration.Cardiac Progenitor Cells in Basic Biology and Regenerative Medicine.Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease
P2860
Q26775715-BD57E94C-7992-4CE0-ACE3-48C635A93519Q35774278-1AD95B68-C3C6-46F4-909C-CABE6AF42184Q37027746-04A061AB-3177-4F94-8A4C-92DAAC039E66Q37152693-64CC8D40-BF08-42CE-82A7-3FA492ADA339Q37378396-CB567B8C-663E-4834-80CC-69B7A745149BQ37659235-5FADBB0C-E9C1-4AA2-977B-49E015CC1AEFQ38846401-E0545B2D-6371-408D-9992-1FBCAAF029B3Q38874087-7645D5F1-F6A3-49E5-9B1F-3356F7149240Q40979831-FC4287CD-8757-4DA1-A50B-EA6A1CDCE5ADQ43192139-CB875DB0-0B0E-4F68-B06E-25763255A41BQ44797293-E831716A-D7CB-4927-BECB-1DC120CCB31BQ46130031-D5A3DE43-0618-4A62-B24B-DD0667DAEB00Q48155889-A41B4A7D-4C11-4FC0-B414-154C3506094BQ52657125-B52A3FF9-521B-4812-8BFA-AD81FE02C3FBQ54945960-8C731A38-BBEC-44D2-A2E4-00D40C8B07EDQ55085484-B0B4B8AD-FF6D-4757-81B5-35DECF75C386Q58562094-6AEE9DC6-C3FC-41BA-A3E8-898A0784683D
P2860
CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@ast
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@en
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@nl
type
label
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@ast
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@en
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@nl
prefLabel
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@ast
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@en
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@nl
P2860
P3181
P356
P1476
CADUCEUS, SCIPIO, ALCADIA: Cel ...... LV dysfunction, still evolving
@en
P2093
John Terrovitis
Magdi H Yacoub
P2860
P3181
P356
10.5339/GCSP.2013.3
P407
P577
2013-01-01T00:00:00Z